ganaxolone - Profile

What are the generic drug sources for ganaxolone and what is the scope of patent protection?

Ganaxolone is the generic ingredient in one branded drug marketed by Marinus and is included in one NDA. There are eleven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ganaxolone has forty-eight patent family members in sixteen countries.

Summary for ganaxolone

International Patents:	48
US Patents:	11
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ganaxolone

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ganaxolone

Constraining patent/regulatory exclusivity:

TREATMENT OF SEIZURES ASSOCIATED WITH CYCLIN-DEPENDENT KINASE-LIKE 5 (CDKL5) DEFICIENCY DISORDER (CDD) IN PATIENTS 2 YEARS OF AGE AND OLDER

Dosage:

SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ganaxolone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes
Marinus	ZTALMY	ganaxolone	SUSPENSION;ORAL	215904-001	Jun 1, 2022		RX	Yes	Yes			Y

EU/EMA Drug Approvals for ganaxolone

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Marinus Pharmaceuticals Emerald Limited	Ztalmy	ganaxolone	EMEA/H/C/005825Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.	Authorised	no	no	yes	2023-07-26

International Patents for ganaxolone

Country	Patent Number	Title	Estimated Expiration
Canada	2631233
Brazil	112019002538	uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
South Korea	20080072760	GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF
Spain	2812250
South Korea	20130123471	GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF
South Korea	101415329
Japan	2019524816	てんかん性障害の処置のための方法および組成物

Supplementary Protection Certificates for ganaxolone

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1959966	122024000005	Germany		PRODUCT NAME: GANAXOLON; REGISTRATION NO/DATE: EU/1/23/1743 20230726
1959966	C202430002	Spain		PRODUCT NAME: GANAXOLONA; NATIONAL AUTHORISATION NUMBER: EU/1/23/1743; DATE OF AUTHORISATION: 20230726; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1743; DATE OF FIRST AUTHORISATION IN EEA: 20230726

Ganaxolone: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Ganaxolone, developed by Marinus Pharmaceuticals, is a synthetic neurosteroid designed for the treatment of epilepsy, neuropsychiatric disorders, and post-traumatic stress disorder. Its unique mechanism as a positive allosteric modulator of GABA_A receptors positions it within a competitive landscape increasingly favoring neurosteroid-based therapies. Despite promising clinical data, market penetration remains contingent on regulatory approvals, competitive advances, and commercialization strategies.

Key financial considerations include ongoing clinical trial costs, potential revenue streams post-approval, and competitive positioning against existing therapies. The current pipeline, regulatory milestones, and health policy landscape influence its investment viability, especially in the short-to-mid term.

---

1. Clinical Development and Regulatory Status

Phase	Status	Key Data & Milestones	Expected Next Steps
Phase 3	Ongoing	ADX-1051 for CDKL5 deficiency disorder; positive topline data	NDA submission targeted for late 2023-2024
Phase 2	Completed	Efficacy in pharmacoresistant epilepsy and postpartum depression	Phase 3 trials for epilepsy and PPD in planning
Preclinical	Approved	Demonstrated safety and pharmacodynamics	Prepare for clinical trials

Sources: [1], [2]

Implication for Investment: Innovations and positive trial outcomes could drive stock appreciation; delays or failures could undermine valuation.

---

2. Market Dynamics

a) Therapeutic Market Size

Indication	Market Estimate (USD)	2022-2027 CAGR	Key Players	Market Drivers
Epilepsy (Rare & drug-resistant)	$8.7B	4.2%	Epidiolex (GW Pharma), Stiripentol	Increasing prevalence, unmet needs
Postpartum Depression	$1.2B	4.9%	Zulresso (Sage), brexanolone	Growing recognition, stigmatization reduction
Neuropsychiatric Disorders	Data emerging	N/A	Off-label use	Expanded indications?

Sources: [3], [4], [5]

b) Competitive Landscape

Key Competitors	Phase	Mechanism	Market Position	Strengths	Weaknesses
Epidiolex (CBD)	Approved	Cannabinoid receptor	Leader in rare epilepsy	Approved, well-established	Regulatory restrictions
Brexanolone/Zulresso	Approved	Neurosteroid	PPD treatment	Rapid onset	High cost, administration complexities
Novel neurosteroids & GABA modulators	Early Pipeline	Various	Potential disruptors	Innovative mechanisms	Unproven efficacy, regulatory hurdles

Sources: [3], [4], [6]

Implication: Ganaxolone’s differentiation hinges on safety, efficacy in difficult-to-treat populations, and favorable administration.

---

3. Commercial and Regulatory Outlook

Key Milestones	Projected Dates	Regulatory Environment	Market Access Considerations
NDA submission for epilepsy	2024	Potential FDA Priority Review	Payer negotiations, reimbursement protocols
Anticipated approvals in Europe & others	2025	EMA and other agencies	Market entry strategies

Policy & Reimbursement: Increasing emphasis on cost-effective neuropsychiatric treatments may influence reimbursement policies. FDA's Accelerated Approval pathway for unmet need indications might accelerate time-to-market.

---

4. Financial Projections and Investment Analysis

Assumption Factors	Baseline Scenario	Upside Scenario	Downside Scenario
Clinical success rate	60%	80%	40%
NDA submission	2024	2024	2025
Peak annual revenue (per indication)	$300M	$450M	$150M
Peak market share (drug-resistant epilepsy)	15%	25%	10%
R&D costs (2023-2028)	$250M	$200M	$300M

Projected Revenue Timeline

Year	Estimated Revenue (USD millions)	Notes
2024	0	NDA filing; awaiting approval
2025	150	Market launch begins (if approved)
2026	300	Increased adoption
2027	450	Peak revenue assuming >20% market share

Note: These figures are speculative and contingent on successful regulatory outcomes.

Investment Risks

Risk Factor	Impact	Mitigation Strategies
Clinical Failure	Major loss	Diversification, pipeline expansion
Regulatory Delays	Revenue deferrals	Pre-approval negotiations, milestone understanding
Competitive Entry	Market share dilution	Differentiation, pricing strategies
Reimbursement Challenges	Reduced profitability	Payer engagement early in development

---

5. Key Market and Investment Drivers

• Clinical efficacy in intractable epilepsy and postpartum depression.
• Regulatory approval and accelerated pathways.
• Market adoption influenced by safety profile and ease of use.
• Competitive landscape shaped by existing neurosteroids and novel GABAergic agents.
• Healthcare policy shifts favoring neuropsychiatric treatments.

---

6. Comparative Analysis: Ganaxolone Versus Competitors

Parameter	Ganaxolone	Epidiolex	Brexanolone	Others
Approval Status	Pending (2024 expected)	Approved 2018	Approved 2019	N/A
Indications	Epilepsy, PPD	Epilepsy, seizures	PPD	Early-stage pipelines
Administration	Oral	Oral	IV	Varies
Market Potential	Expanding	Established	Niche	Emerging

---

Key Takeaways

• Clinical milestones in 2024-2025 will significantly influence Ganaxolone’s valuation.
• Market size and unmet needs in epilepsy and PPD provide promising growth opportunities.
• Competitive advantages include a favorable safety profile and oral administration, but market entry is challenged by existing approved therapies.
• Investment risks are mainly clinical and regulatory; diversifying portfolio exposure to related neurosteroid therapeutics is advisable.
• Early engagement with payers and policymakers can facilitate market access and reimbursement success.

---

FAQs

1. What are the key clinical milestones for Ganaxolone in the next 12-24 months?
NDA submission anticipated in late 2023 or 2024, with Phase 3 data for epilepsy and postpartum depression expected to support this initiative.

2. How does Ganaxolone compare to existing therapies in treating epilepsy?
Ganaxolone offers a novel mechanism with a favorable safety profile, potentially effective in drug-resistant populations, but must demonstrate superior efficacy or safety to gain market share over established treatments like Epidiolex.

3. What are the regulatory pathways that support Ganaxolone’s approval?
The FDA may consider Fast Track and Priority Review designations, especially if data support unmet medical needs. EMA and other agencies may provide conditional approvals or accelerated pathways.

4. What is the potential market size for Ganaxolone?
Cumulatively, epilepsy and postpartum depression markets could exceed $10 billion globally, with growth driven by increasing prevalence, diagnosis rates, and expanded indications.

5. What strategic considerations should investors monitor?
Track clinical trial outcomes, regulatory approvals, competitive developments, partnership agreements, and reimbursement policies influencing commercialization.

---

References

[1] Marinus Pharmaceuticals. "Ganaxolone Program Overview," 2022.
[2] U.S. FDA. "Quick Facts: Ganaxolone," 2023.
[3] Grand View Research. "Epilepsy Drugs Market Analysis," 2022.
[4] MarketWatch. "Postpartum Depression Treatments Market Size," 2022.
[5] IQVIA. "Neuropsychiatric Therapeutics Outlook," 2023.
[6] FiercePharma. "Neurosteroids in Development," 2022.